BACKGROUND/AIMS: Resembling a potential therapeutic drug target, fibroblast growth factor receptor 1 (FGFR1) amplification and expression was assessed in 515 human colorectal cancer (CRC) tissue samples, lymph node metastases and CRC cell lines. METHODS: FGFR1 amplification status was determined using fluorescence in situ hybridization. Additionally, we assessed protein levels employing Western blots and immunohistochemistry. The FGFR1 mRNA localization was analyzed using mRNA in situ hybridization. Functional studies employed the FGFR inhibitor NVP-BGJ398. RESULTS: Of 454 primary CRCs, 24 displayed FGFR1 amplification. 92/94 lymph node metastases presented the same amplification status as the primary tumor. Of 99 investigated tumors, 18 revealed membranous activated pFGFR1 protein. FGFR1 mRNA levels were independent of the amplification status or pFGFR1 protein occurrence. In vitro, a strong antiproliferative effect of NVP-BGJ398 could be detected in cell lines exhibiting high FGFR1 protein. CONCLUSION: FGFR1 is a potential therapeutic target in a subset of CRC. FGFR1 protein is likely to represent a central factor limiting the efficacy of FGFR inhibitors. The lack of correlation between its evaluation at genetic/mRNA level and its protein occurrence indicates that the assessment of the receptor at an immunohistochemical level most likely represents a suitable way to assess FGFR1 as a predictive biomarker for patient selection in future clinical trials.
BACKGROUND/AIMS: Resembling a potential therapeutic drug target, fibroblast growth factor receptor 1 (FGFR1) amplification and expression was assessed in 515 humancolorectal cancer (CRC) tissue samples, lymph node metastases and CRC cell lines. METHODS:FGFR1 amplification status was determined using fluorescence in situ hybridization. Additionally, we assessed protein levels employing Western blots and immunohistochemistry. The FGFR1 mRNA localization was analyzed using mRNA in situ hybridization. Functional studies employed the FGFR inhibitor NVP-BGJ398. RESULTS: Of 454 primary CRCs, 24 displayed FGFR1 amplification. 92/94 lymph node metastases presented the same amplification status as the primary tumor. Of 99 investigated tumors, 18 revealed membranous activated pFGFR1 protein. FGFR1 mRNA levels were independent of the amplification status or pFGFR1 protein occurrence. In vitro, a strong antiproliferative effect of NVP-BGJ398 could be detected in cell lines exhibiting high FGFR1 protein. CONCLUSION:FGFR1 is a potential therapeutic target in a subset of CRC. FGFR1 protein is likely to represent a central factor limiting the efficacy of FGFR inhibitors. The lack of correlation between its evaluation at genetic/mRNA level and its protein occurrence indicates that the assessment of the receptor at an immunohistochemical level most likely represents a suitable way to assess FGFR1 as a predictive biomarker for patient selection in future clinical trials.
Authors: Kentaro Nakao; Kshama R Mehta; Jane Fridlyand; Dan H Moore; Ajay N Jain; Amalia Lafuente; John W Wiencke; Jonathan P Terdiman; Frederic M Waldman Journal: Carcinogenesis Date: 2004-03-04 Impact factor: 4.944
Authors: Brigitte Lankat-Buttgereit; Sabine Müller; Harald Schmidt; Klaus G Parhofer; Thomas M Gress; Rüdiger Göke Journal: Biol Cell Date: 2008-12 Impact factor: 4.458
Authors: S Perner; P L Wagner; A Soltermann; C LaFargue; V Tischler; B A Weir; W Weder; M Meyerson; T J Giordano; H Moch; M A Rubin Journal: J Pathol Date: 2009-01 Impact factor: 7.996
Authors: Michal K Stachowiak; Xiaohong Fang; Jason M Myers; Star M Dunham; Ronald Berezney; Pamela A Maher; Ewa K Stachowiak Journal: J Cell Biochem Date: 2003-11-01 Impact factor: 4.429
Authors: Laura D Wood; D Williams Parsons; Siân Jones; Jimmy Lin; Tobias Sjöblom; Rebecca J Leary; Dong Shen; Simina M Boca; Thomas Barber; Janine Ptak; Natalie Silliman; Steve Szabo; Zoltan Dezso; Vadim Ustyanksky; Tatiana Nikolskaya; Yuri Nikolsky; Rachel Karchin; Paul A Wilson; Joshua S Kaminker; Zemin Zhang; Randal Croshaw; Joseph Willis; Dawn Dawson; Michail Shipitsin; James K V Willson; Saraswati Sukumar; Kornelia Polyak; Ben Ho Park; Charit L Pethiyagoda; P V Krishna Pant; Dennis G Ballinger; Andrew B Sparks; James Hartigan; Douglas R Smith; Erick Suh; Nickolas Papadopoulos; Phillip Buckhaults; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein Journal: Science Date: 2007-10-11 Impact factor: 47.728
Authors: Hu Peng; Jason Myers; Xiaohong Fang; Ewa K Stachowiak; Pamela A Maher; Gabriel G Martins; Gabriela Popescu; Ronald Berezney; Michal K Stachowiak Journal: J Neurochem Date: 2002-05 Impact factor: 5.372
Authors: Eva Bandres; Xabier Agirre; Nerea Bitarte; Natalia Ramirez; Ruth Zarate; Jose Roman-Gomez; Felipe Prosper; Jesus Garcia-Foncillas Journal: Int J Cancer Date: 2009-12-01 Impact factor: 7.396
Authors: Friederike Göke; Alina Franzen; Trista K Hinz; Lindsay A Marek; Petros Yoon; Rakesh Sharma; Maike Bode; Anne von Maessenhausen; Brigitte Lankat-Buttgereit; Antonia Göke; Carsten Golletz; Robert Kirsten; Diana Boehm; Wenzel Vogel; Emily K Kleczko; Justin R Eagles; Fred R Hirsch; Tobias Van Bremen; Friedrich Bootz; Andreas Schroeck; Jihye Kim; Aik-Choon Tan; Antonio Jimeno; Lynn E Heasley; Sven Perner Journal: Clin Cancer Res Date: 2015-05-26 Impact factor: 12.531
Authors: A L Cisyk; S Penner-Goeke; Z Lichtensztejn; Z Nugent; R H Wightman; H Singh; K J McManus Journal: Neoplasia Date: 2015-03 Impact factor: 5.715
Authors: Erica J Peterson; A Gerard Daniel; Samantha J Katner; Lisa Bohlmann; Chih-Wei Chang; Anna Bezos; Christopher R Parish; Mark von Itzstein; Susan J Berners-Price; Nicholas P Farrell Journal: Chem Sci Date: 2016-08-12 Impact factor: 9.825
Authors: Julia Elisabeth Fromme; Katja Schmitz; Astrid Wachter; Marius Grzelinski; Dirk Zielinski; Christina Koppel; Lena-Christin Conradi; Kia Homayounfar; Tabea Hugo; Sara Hugo; Laura Lukat; Josef Rüschoff; Philipp Ströbel; Michael Ghadimi; Tim Beißbarth; Kirsten Reuter-Jessen; Annalen Bleckmann; Hans-Ulrich Schildhaus Journal: Oncotarget Date: 2018-08-14